Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP14 | P50281 | 1/20 | 0.35 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL67921 | 0.87 | PPARA (0.41) | PPARANR4A2MAOBTP53MAPT | |
| Hydrochloric Acid SCHEMBL69414 | 0.86 | MAOB (0.44) | PPARANR4A2MAOBTP53MAPT | |
| SCHEMBL68159 | 0.85 | LMNA (0.46) | PPARALMNAKMT2A | |
| SCHEMBL4649918 | 0.83 | PPARA (0.39) | PPARANR4A2MAOBTP53MAPT | |
| SCHEMBL69070 | 0.83 | MRGPRX4 (0.46) | PPARANR4A2MAOBTP53MAPT | |
| Hydrochloric Acid SCHEMBL70566 | 0.82 | PPARA (0.40) | PPARANR4A2MAOBTP53MAPT | |
| Hydrochloric Acid SCHEMBL67918 | 0.82 | PPARA (0.39) | PPARANR4A2MAOBTP53MAPT | |
| SCHEMBL67655 | 0.82 | MAPT (0.45) | NR4A2MAOBTP53MAPTMRGPRX4 | |
| SCHEMBL67451 | 0.82 | MAOB (0.41) | PPARANR4A2MAOBTP53MAPT | |
| Hydrochloric Acid SCHEMBL69592 | 0.81 | MAOB (0.41) | PPARANR4A2MAOBTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470877-B2 | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2013-06-25 | — | — | US | disclosed |
| CN-101309909-B | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators | NEWRON PHARM SPA | 2012-11-14 | — | — | CN | disclosed |
| US-20120220592-A1 | 2-PHENYLETHYLAMINO DERIVATIVES AS CALCIUM AND/OR SODIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2012-08-30 | — | — | US | disclosed |
| US-8129427-B2 | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2012-03-06 | — | — | US | disclosed |
| US-20110046129-A1 | 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-02-24 | — | — | US | disclosed |
| US-7855227-B2 | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-12-21 | — | — | US | disclosed |
| US-20080319057-A1 | 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators | NEWRON PHARMACEUTICALS S.P.A. | 2008-12-25 | — | — | US | disclosed |
| CN-101309909-A | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators | NEWRON PHARM SPA (IT) | 2008-11-19 | — | — | CN | disclosed |
| EP-1963280-A1 | 2 -PHENYLETHYLAMINO DERIVATIVES AS CALCIUM AND/OR SODIUM CHANNEL MODULATORS | Newron Pharmaceuticals S.p.A. (IT) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007071311-A1 | 2 -PHENYLETHYLAMINO DERIVATIVES AS CALCIUM AND/OR SODIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319057-A1 | 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators | CACNA1A, CACNA1E, CACNA1I | PPARA 1950/4885NR4A2 807/4885MAOB 1068/4885 |
| US-20110046129-A1 | 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators | CACNA1A, CACNA1I, KCNN2 | PPARA 1574/4885NR4A2 1006/4885MAOB 2154/4885 |
| US-20120220592-A1 | 2-PHENYLETHYLAMINO DERIVATIVES AS CALCIUM AND/OR SODIUM CHANNEL MODULATORS | CACNA1A, CACNA1I, KCNN2 | PPARA 1574/4885NR4A2 1006/4885MAOB 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.